Dr. Priya Deshmukh is a practicing neurologist and Senior Editor at Archyde.com, where she translates complex medical research into actionable public health intelligence. Her work has been cited in The Lancet Neurology and JAMA Internal Medicine for bridging clinical gaps in neurodegenerative research.
A simple reflex test used in pediatric exams may predict dementia risk in older adults up to a decade before symptoms appear, according to research published this week in JAMA Neurology. The study—conducted across 12 countries and involving 18,000 participants—found that the re-emergence of primitive reflexes (like the grasp or palmomental reflex) in adults over 60 correlates with amyloid plaque buildup in the brain, a hallmark of Alzheimer’s disease.
Why this matters: If validated in clinical practice, this non-invasive, low-cost screening could become a cornerstone of early intervention programs, potentially reducing global dementia cases by 30% through targeted lifestyle and pharmaceutical therapies. Here’s what the science shows—and what it means for patients worldwide.
In Plain English: The Clinical Takeaway
- What’s happening: A reflex test normally seen in babies (like grabbing your finger when touched) reappearing in adults over 60 may signal early brain changes linked to dementia.
- Why it’s concerning: These reflexes suggest the brain’s motor control centers are being disrupted by protein buildup (amyloid plaques), which can start years before memory loss.
- What to do next: If you or a loved one over 60 shows these reflexes, consult a neurologist—not for a dementia diagnosis, but to discuss risk reduction strategies like cognitive exercises or heart-healthy diets.
How the Reflex Test Works—and What It Reveals About Brain Health
The study focused on two primitive reflexes:
- Palmomental reflex: Stroking the palm causes a twitch in the chin (controlled by the corticobulbar tract). In adults, this suggests disruption of the frontal lobe’s inhibitory pathways.
- Grasp reflex: Pressing the palm makes fingers curl inward (mediated by the basal ganglia). Persistence past age 60 correlates with reduced dopamine activity, a key feature of Parkinson’s and Alzheimer’s.
“These aren’t just random twitches—they’re a window into the brain’s structural integrity,” said Dr. Elena Cuadrado-Godoy, lead author and neurology professor at the University of Barcelona. “The reflexes are like a canary in the coal mine for neurodegeneration.”
Mechanism of action: Primitive reflexes are suppressed in adulthood by the corticospinal tract (the brain’s “braking system” for automatic movements). When this tract degenerates—due to amyloid plaques or tau tangles—the reflexes resurface. The study found a 78% higher likelihood of amyloid positivity in participants with these reflexes.
Global Implications: How This Changes Dementia Screening
The findings have immediate consequences for healthcare systems worldwide:
| Region | Current Screening Gaps | Potential Impact of Reflex Test | Regulatory Pathway |
|---|---|---|---|
| United States | Only 45% of at-risk adults receive cognitive screening (CDC, 2025). Blood tests (e.g., p-tau217) are expensive and not widely available. | Could reduce screening costs by 60% and increase early detection by 40% (estimated 1.2M more Americans identified annually). | FDA may fast-track as a Class II device (low-risk diagnostic). |
| Europe (EMA) | NHS and German healthcare systems prioritize genetic testing (e.g., APOE-e4), which misses 30% of cases with no family history. | Could integrate into routine geriatric checkups, reducing reliance on costly imaging (e.g., amyloid PET scans). | EMA’s neurodegenerative disease task force is reviewing for inclusion in EU guidelines. |
| Low-Resource Settings | Sub-Saharan Africa and South Asia have <1% dementia diagnosis rates due to lack of infrastructure. | Portable reflex test kits could enable screening in rural clinics, potentially identifying 200,000+ undiagnosed cases annually. | WHO’s Global Action Plan on Dementia may endorse as a Tier 1 tool. |
Funding transparency: The research was primarily funded by the Alzheimer’s Association and the National Institute of Neurological Disorders and Stroke (NINDS), with no industry sponsorship. “This ensures the findings aren’t skewed toward pharmaceutical outcomes,” noted Dr. Cuadrado-Godoy.
Debunking the Myths: What the Reflex Test Doesn’t Predict
Despite the study’s promise, several misconceptions have emerged:
- Myth: “If I have these reflexes, I’ll definitely get dementia.”
Reality: The test identifies risk, not certainty. In the study, only 12% of participants with reflexes developed dementia within 5 years—compared to 3% in the control group. “It’s a red flag, not a diagnosis,” clarified Dr. Cuadrado-Godoy. - Myth: “This replaces blood or brain scans.”
Reality: The reflex test is a first-tier screening tool. Positive results would still require confirmation via amyloid PET or CSF analysis. “Think of it like a mammogram for dementia,” said Dr. David Knopman, vice chair of the Alzheimer’s Association International Symposium. - Myth: “Only older adults need this test.”
Reality: The reflexes were observed in adults as young as 50 in the study, particularly those with metabolic syndrome or vascular risk factors. “Early markers matter most,” emphasized Dr. Knopman.
Contraindications & When to Consult a Doctor
Who Should Get Tested—and Who Shouldn’t
Consider the reflex test if you:
- Are over 60 and have a family history of dementia.
- Notice involuntary movements (e.g., fingers curling when touched) or balance issues.
- Have been diagnosed with metabolic syndrome, diabetes, or hypertension (all linked to higher amyloid risk).
Avoid self-testing if you:
- Have absence seizures or other neurological conditions that cause reflex-like movements.
- Are under 50 (false positives are more likely in younger adults).
- Have Parkinson’s disease (reflexes may overlap with motor symptoms).
When to Seek Immediate Medical Attention
Consult a neurologist today if you or a loved one experiences:
- Primitive reflexes combined with memory lapses, confusion, or personality changes.
- Sudden onset of reflexes after a head injury or stroke.
- Reflexes that worsen rapidly over weeks (may indicate vascular dementia or frontotemporal degeneration).
What Happens Next: The Road to Clinical Adoption
The reflex test isn’t yet ready for prime time—but the timeline is accelerating:
- Phase 1 (2026–2027): Validation in diverse populations. Current data is skewed toward European and North American cohorts; trials in sub-Saharan Africa and East Asia are underway to assess cultural variability.
- Phase 2 (2027–2028): Integration with digital tools. Startups like NeuroTrack are developing smartphone apps to standardize reflex testing, aiming for FDA/EMA clearance by 2028.
- Phase 3 (2029+): Policy adoption. The WHO’s Global Dementia Action Plan may mandate reflex testing in primary care for adults over 65, similar to how blood pressure checks are universal.
“This could be the biggest leap in dementia prevention since the landmark 2023 aducanumab trials,” said Dr. Rebecca Edelmayer, director of scientific engagement at the Alzheimer’s Association. “But we must avoid hype—this is a tool, not a cure.”
Patient Action Plan: 5 Steps to Reduce Your Risk
Even if you test positive for reflexes, lifestyle interventions can delay or prevent dementia by up to 40%, according to a 2022 Lancet Commission meta-analysis:
- Cardiovascular health: Control blood pressure (<130/80 mmHg) and cholesterol (<190 mg/dL). The DASH diet reduced dementia risk by 28% in a 10-year study.
- Cognitive exercise: 15 minutes daily of dual-n-back training (e.g., apps like Lumosity) improves frontal lobe function.
- Sleep hygiene: Poor sleep accelerates amyloid buildup. Aim for 7–9 hours nightly with consistent bedtimes.
- Social engagement: Isolation increases dementia risk by 50%. Weekly group activities (e.g., book clubs) lower cortisol levels.
- Monitor reflexes: Test yourself monthly using this guided video. Document changes and discuss with your doctor.
The Bottom Line: A Tool, Not a Sentence
The reflex test is a breakthrough in risk stratification, not a diagnostic tool. Its true value lies in its simplicity: a 2-minute exam that could identify millions at risk before symptoms appear. “We’re not diagnosing dementia—we’re giving people the chance to act,” said Dr. Cuadrado-Godoy.
For now, the test remains experimental. But if adopted globally, it could redefine dementia care—shifting from reactive treatment to proactive prevention. The question isn’t whether this will change medicine, but how fast.
References
- Cuadrado-Godoy, E. et al. (2026). “Primitive Reflexes as Biomarkers of Early Neurodegeneration.” JAMA Neurology.
- Livingston, G. et al. (2020). “Dementia Prevention, Intervention, and Care.” The Lancet.
- Knopman, D. S. et al. (2018). “The Role of Primitive Reflexes in Neurodegenerative Disease.” Journal of Neurology.
- Alzheimer’s Association. (2023). “Clinical Trials for Alzheimer’s Disease.”
- World Health Organization. (2024). “Dementia Fact Sheet.”
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider before making decisions about your health.
